Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States
Antimicrobial Agents and Chemotherapy · 05.03.2025 · 69 (3)
DOI: 10.1128/aac.01258-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.03.2025. Verfasst von Dariusz A Hareza und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: beta-Lactamases, Anti-Bacterial Agents, Ceftriaxone, Enterobacteriaceae Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCEZID CDC HHS, HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
Ceftriaxone-resistant Enterobacterales remain a public health threat; contemporary data investigating their molecular epidemiology are limited. Five hundred consecutive ceftriaxone-resistant (MIC ≥ 4 µg/mL) Enterobacterales bloodstream isolates were collected between 2018 and 2022 from three Maryland hospitals. Broth microdilution confirmed antibiotic susceptibilities. Whole-genome sequencing identified extended-spectrum β-lactamase (ESBL) and ampC genes both in bacterial chromosomes (c- ampC ) and on plasmids (p- ampC ). Mutations in promoter or attenuator regions of the Escherichia coli c- ampC gene (i.e., bla EC gene) with the potential to result in ampC derepression were investigated. The presence of ESBL or ampC genes was confirmed in 497 (99.4%) isolates. Two hundred seventy-nine (55.8%) isolates had both ESBL and ampC genes. ESBL families were identified among 398 (80%) patients: bla CTX-M ( n = 370), bla SHV ( n = 17), bla OXY ( n = 14), and bla VEB ( n = 5). Ceftriaxone-resistant Enterobacterales species carrying ESBL genes included the following: E. coli (67%), Klebsiella pneumoniae (24%), Klebsiella oxytoca (4%), Proteus mirabilis (2%), Enterobacter cloacae complex (2%), Klebsiella aerogenes (1%), Providencia stuartii (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Microbiology and Immunology, Creighton School of Medicine, Omaha, Nebraska, USA.
- Ares Genetics, Vienna, Austria.
- Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Patricia J Simner, Pranita D Tamma
Förderung
- NIAID NIH HHS
- NCEZID CDC HHS
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Hareza, D. A., Bergman, Y., Jacobs, E., Lu, J., Hanson, N. D., Conzemius, R., Cosgrove, S. E., Harris, A. D., Simner, P. J., & Tamma, P. D. (2025). Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States. Antimicrobial Agents and Chemotherapy, 69(3). https://doi.org/10.1128/aac.01258-24
Vancouver
Hareza DA, Bergman Y, Jacobs E, Lu J, Hanson ND, Conzemius R, et al. Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States. Antimicrobial Agents and Chemotherapy. 2025;69(3). doi:10.1128/aac.01258-24
BibTeX
@article{Hareza2025,
author = {Hareza, Dariusz A and Bergman, Yehudit and Jacobs, Emily and Lu, Jennifer and Hanson, Nancy D and Conzemius, Rick and Cosgrove, Sara E and Harris, Anthony D and Simner, Patricia J and Tamma, Pranita D},
title = {Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {3},
doi = {10.1128/aac.01258-24}
}
EUVIMED